Defective signal transduction by the CD2 molecule in immature T-cell receptor/CD3- thymocytes.

Abstract

The

Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression

“…2B). This is in sharp contrast with the PMAinduced CD28 regulation in CD8 + T cells where optimal CD28 expression is observed 72 h after PMA stimulation [21].…”

“…Since PMA, a well-known neutrophil activator, modulates CD28 expression on human T cells [21], we examined if treatment of neutrophils with PMA modulated CD28 expression. Stimulation of these cells with PMA showed an up-regulation of surface CD28 expression in a dose-dependent manner, the optimum dose being 50 ng/ml ( Fig.…”

“…Therefore, the inhibition of PMA-induced CD28 expression by staurosporin suggested that signaling through PKC is required for PMA-enhanced CD28 expression. Since CD28 on T cells is inducible by PMA stimulation, as checked by increase in RNA transcripts [21], we tested if the transcription inhibitor could block the PMAinduced CD28 up-regulation on neutrophils surface. Actinomycin D, a transcription inhibitor [23], blocked the PMA-induced CD28 up-regulation significantly, suggesting that active RNA synthesis is required for PMAinduced up-regulation of CD28 expression on neutrophils (Fig.…”

Inhibition of Transmethylation Down-Regulates CD4 T Cell Activation and Curtails Development of Autoimmunity in a Model System

“…Each sample was warmed to 37°C before analysis. Baseline fluorescence was monitored for ϳ2 min before addition of avidin (60 g/ml; Vector Laboratories) to cross-link the biotinylated anti-CD3/CD28 Abs (20). Calcium flux data were acquired for 10 -15 min at 351 nm on a LSR II flow cytometer (BD Biosciences) and analyzed with FlowJo software.…”

A Phase I/II Randomized Open-Label Multicenter Trial of Efalizumab, a Humanized Anti-CD11a, Anti-LFA-1 in Renal Transplantation

“…This approach may be particularly useful for recipients of renal allografts from extended criteria donors and/or those that develop delayed graft function. Biologic agents that target novel targets such as costimulation pathways or adhesion pathways have been shown to induce tolerance in rodents and prolong graft survival in nonhuman primates (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). An important therapeutic target for inhibition with biologic agents is the leukocyte function associated antigen 1 (LFA-1), best known as a classic adhesion molecule (22,23).…”